NASDAQ:PHIO Phio Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.13 +0.03 (+1.43 %) (As of 09/29/2020 12:00 AM ET) Add Compare Share Today's Range$2.08Now: $2.13▼$2.1650-Day Range$1.95MA: $2.32▼$2.9452-Week Range$1.60Now: $2.13▼$18.15Volume79,443 shsAverage Volume714,282 shsMarket Capitalization$12.31 millionP/E RatioN/ADividend YieldN/ABeta2.36 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. The company has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingPhio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Phio Pharmaceuticals has a forecasted upside of 86.9% from its current price of $2.14.Amount of Analyst CoveragePhio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesPhio Pharmaceuticals has received 29 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPhio Pharmaceuticals has received 30 “underperform” votes. (Add your “underperform” vote.)Community SentimentPhio Pharmaceuticals has received 50.85% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Phio Pharmaceuticals and other stocks. Vote “Outperform” if you believe PHIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PHIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPhio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhio Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phio Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.52% of the stock of Phio Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 2.26% of the stock of Phio Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Phio Pharmaceuticals are expected to grow in the coming year, from ($2.23) to $0.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phio Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phio Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPhio Pharmaceuticals has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.05 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PHIO Previous Symbol CUSIPN/A CIKN/A Webphiopharma.com Phone508-767-3861Debt Debt-to-Equity Ratio0.03 Current Ratio10.33 Quick Ratio10.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales615.57 Cash FlowN/A Price / Cash FlowN/A Book Value$8.59 per share Price / Book0.25Profitability EPS (Most Recent Fiscal Year)($19.33) Net Income$-8,910,000.00 Net MarginsN/A Return on Equity-81.51% Return on Assets-66.70%Miscellaneous Employees9 Outstanding Shares5,780,000Market Cap$12.31 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $2.13 +0.03 (+1.43 %) (As of 09/29/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PHIO News and Ratings via Email Sign-up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions How has Phio Pharmaceuticals' stock been impacted by Coronavirus? Phio Pharmaceuticals' stock was trading at $2.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PHIO shares have decreased by 23.1% and is now trading at $2.13. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Phio Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Phio Pharmaceuticals. When is Phio Pharmaceuticals' next earnings date? Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Phio Pharmaceuticals. How were Phio Pharmaceuticals' earnings last quarter? Phio Pharmaceuticals Corp (NASDAQ:PHIO) issued its earnings results on Wednesday, August, 12th. The company reported ($0.34) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.31. View Phio Pharmaceuticals' earnings history. What price target have analysts set for PHIO? 1 brokers have issued twelve-month target prices for Phio Pharmaceuticals' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Phio Pharmaceuticals' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 87.8% from the stock's current price. View analysts' price targets for Phio Pharmaceuticals. Are investors shorting Phio Pharmaceuticals? Phio Pharmaceuticals saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 15,700 shares, a decline of 80.4% from the August 31st total of 80,000 shares. Based on an average trading volume of 482,300 shares, the short-interest ratio is currently 0.0 days. Currently, 0.3% of the company's stock are sold short. View Phio Pharmaceuticals' Short Interest. Who are some of Phio Pharmaceuticals' key competitors? Some companies that are related to Phio Pharmaceuticals include Kazia Therapeutics (KZIA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT), Stealth BioTherapeutics (MITO), Newron Pharmaceuticals (NWPHF), CohBar (CWBR), ProPhase Labs (PRPH), Addex Therapeutics (ADDXF), KemPharm (KMPH), KemPharm (KMPH), Acerus Pharmaceuticals (ASPCF), Forward Pharma A/S (FWP), Sernova (SEOVF), Ceapro (CRPOF) and IMMURON LTD/S (IMRN). View all competitors. What other stocks do shareholders of Phio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Vaxart (VXRT), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC) and Jaguar Health (JAGX). Who are Phio Pharmaceuticals' key executives? Phio Pharmaceuticals' management team includes the following people: Dr. Gerrit Dispersyn Ph.D., Dr. Med. Sc, Pres & CEO (Age 44)Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 33) What is Phio Pharmaceuticals' stock symbol? Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO." How do I buy shares of Phio Pharmaceuticals? Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Phio Pharmaceuticals' stock price today? One share of PHIO stock can currently be purchased for approximately $2.13. How big of a company is Phio Pharmaceuticals? Phio Pharmaceuticals has a market capitalization of $12.31 million and generates $20,000.00 in revenue each year. The company earns $-8,910,000.00 in net income (profit) each year or ($19.33) on an earnings per share basis. Phio Pharmaceuticals employs 9 workers across the globe. What is Phio Pharmaceuticals' official website? The official website for Phio Pharmaceuticals is phiopharma.com. How can I contact Phio Pharmaceuticals? Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at 508-767-3861 or via email at [email protected] This page was last updated on 9/29/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
